Leqembi launched in India for early Alzheimer’s after CDSCO approval
Eisai has launched Leqembi, or lecanemab, in India for patients with mild cognitive impairment and mild dementia caused by early Alzheimer’s disease, after receiving marketing authorisation from the Central Drugs Standard Control…
Ashin Xavier: interesting
IO Repro: Repro test v4 after fix 2 Oct. Safe to trash.
IO Repro: Repro test v3 after fix 2 Oct. Safe to trash.
IO Repro: Repro test after fix 2 Oct. Safe to trash.